Pharmacyclics-heading Uphill On Cancer Drug Push

Boston, MA 02/19/2013 (wallstreetpr)- Pharmacyclics, Inc (NASDAQ:PCYC) has been working in collaboration with Johnson & Johnson (NYSE:JNJ) on Ibrutinib, the leukemia and mantle cell lymphoma treatment drug. Late 2014 would see the launch of the very first drug that the company would be selling if it gets market approved by FDA.

In 2012, FDA had launched a breakthrough therapy program which made speedy approval possible for drugs that were deemed fit to be categorized as significantly better treatments for existing life-threatening or serious diseases.

Breakthrough profitability

The breakthrough announcement that Pharmacyclics, Inc (NASDAQ:PCYC) made sent its shares skyrocketing last Friday and its shares touched an all-time high as it closed at $87, up by $6.79,  which was a phenomenal rise of 8.5%. A 24 % surge over three days and the company is looking forward to sales touching $158 million by 2015.

Pharmacyclics, Inc (NASDAQ:PCYC) quarterly results were reported last week and it had seen a dip of 56 cents per share from the 78 cents. Its earnings had taken a downturn from $56.3 million to $41.9 million over the last 3 months. This was primarily because it saw a reduction in the licensing payments that it received from companies such as Johnson & Johnson (NYSE:JNJ) and Novo Nordisk A/S (ADR) (NYSE:NVO) as well as an increase in research and development costs.

The company saw its net income almost tripling to $117.5 million, an increasing by $1.58 per share. Its revenue close to doubled when it hit $160.7 million up from $77.9 million. The company will also be switching from the June ending fiscal year to  the December ending one.

For consideration of being featured on WallstreetPR, contact:

Please make sure to read and completely understand our disclaimer at FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any content posted on our website is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. WallStreetPR strongly recommends you consult a licensed or registered professional before making any investment decision. Neither nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. WallStreetPR often gets compensated for advertisement services that are disclosed on our disclaimer located at

Published by Brendan Byrne

While studying economics, Brendan found himself comfortably falling down the rabbit hole of restaurant work, ultimately opening a consulting business and working as a private wine buyer. On a whim, he moved to China, and in his first week following a triumphant pub quiz victory, he found himself bleeding on the floor based on his arrogance. The same man who put him there offered him a job lecturing for the University of Wales in various sister universities throughout the Middle Kingdom. While primarily lecturing in descriptive and comparative statistics, Brendan simultaneously earned an Msc in Banking and International Finance from the University of Wales-Bangor. He's presently doing something he hates, respecting French people. Well, two, his wife and her mother in the lovely town of Antigua, Guatemala. You may contact Brendan via his email ( or his Google+ page (